MK0767 and Sulfonylurea Combination Study (0767-027)

Phase 3

Terminated

• Conditions: Diabetes Mellitus, Type 2

• Registration Number: NCT00543491
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will assess MK0767's ability vs. placebo to control blood glucose in patients with type 2 diabetes and to gauge whether fasting blood glucose is lowered, blood fats are improved, and insulin levels are impacted.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2003-05
• Primary Completion: 2003-12
• Study Completion: 2003-12
• Study First Submitted: 2007-10-05
• Study First Submitted QC: 2007-10-12
• Study First Posted: 2007-10-15
• Status Verified: 2015-06
• Last Update Submitted: 2015-06-11
• Last Update Posted: 2015-06-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 129

Inclusion Criteria

• Type 2 Diabetes with inadequate glycemic control
• On Sulfonylurea monotherapy
• Male or non-pregnant Females
• Age 21 to 78 years, inclusive
• On a stable dose of sulfonylurea for at least 2 weeks prior to Visit 2/Week-6

Read More

Exclusion Criteria

• History of Type 1 diabetes
• Patient is currently on insulin (monotherapy or in combination with oral agent), Rosiglitazone or pioglitazone or other PPAR-y agonists, Metformin agents
• Patients with history of or intolerance of PPAR-y agonists

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP